The $28-billion bond issue will be the fourth largest in history.
AbbVie plans to close on its $63-billion buyout of Allergan in early 2020. To finance the deal, the company is issuing a $28-billion dollar bond, the fourth largest in history according to Bloomberg.
The merged companies will qualify as the fourth largest drug manufacturer in the world. Combined in 2019 they generated $19 billion in cash, so AbbVie CEO Richard Gonzalez is not worried about taking on the debt.
Earlier in 2019, Bristol-Myers Squibb issued $19 billion in bonds to partially finance its $74-billion Celgene acquisition, which is expected to close by the end of 2019.
Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.